Real-World Data Shows Semaglutide 2.4mg Lowers Heart Event Risk in ASCVD Patients

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study. Authors: Nanna MG, Mena-Hurtado C, Divino…